Literature DB >> 28521422

Clinical outcomes and prognostic factors of resected pancreatic neuroendocrine neoplasms: A single-center experience in China.

Kaizhou Jin1,2,3, Guopei Luo1,2,3, Jin Xu1,2,3, Bo Zhang1,2,3, Chen Liu1,2,3, Shunrong Ji1,2,3, Liang Liu1,2,3, Jiang Long1,2,3, Quanxing Ni1,2,3, Xianjun Yu1,2,3.   

Abstract

The aim of the present study was to investigate the clinical, pathological and prognostic characteristics of Chinese patients with resected pancreatic neuroendocrine neoplasms (p-NENs). Data from patients who were surgically treated and pathologically diagnosed with p-NENs at the Department of Pancreatic Oncology of the Fudan University Shanghai Cancer Center (Shanghai, China), between January 2003 and July 2015, were evaluated using univariate and multivariate analyses. A total of 162 patients with p-NENs met the criteria of the present study and were included in the analysis. Patients with poorly differentiated pancreatic neuroendocrine carcinoma (p-NEC) exhibited a significantly increased rate of lymph node metastasis, as compared with patients with grade (G)1/G2 pancreatic neuroendocrine tumors (p-NETs) (62.5 vs. 20.5%, P=0.003). Univariate analysis identified that the following factors led to decreased overall survival (OS): Lymph node metastasis (P=0.001, vs. the absence of lymph node metastasis); distant metastasis (P=0.043, vs. the absence of distant metastasis); resection margin R1/R2 (P=0.030, vs. R0 resection); NEC G3 (P<0.001, vs. NET G1). Following the multivariate analysis, NEC G3 remained a statistically significant risk factor (HR=12.593; 95% CI, 3.476-45.622; P<0.001, vs. NET G1/G2). Furthermore, according to the proliferation marker protein Ki-67 staining index, assigning a grade using the proliferative index (G1, ≤5%; G2, >5-20%; G3, >20%) was more efficient for prognostic stratification compared with the European Neuroendocrine Tumor Society (Berlin, Germany)/World Health Organization (Geneva, Switzerland) 2010 grading classification. The present study indicated that p-NEC was an important predictor of decreased OS in Chinese patients. Furthermore, a Ki-67 staining index of 5% represented a more efficient value for the distinction between G1 and G2.

Entities:  

Keywords:  clinical outcome; neuroendocrine neoplasm; pancreas; prognostic factor

Year:  2017        PMID: 28521422      PMCID: PMC5431258          DOI: 10.3892/ol.2017.5834

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  25 in total

Review 1.  Revised classification of neuroendocrine tumours of the lung, pancreas and gut.

Authors:  C Capella; P U Heitz; H Höfler; E Solcia; G Klöppel
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

2.  Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors.

Authors:  Jonathan R Strosberg; Asima Cheema; Jill Weber; Gang Han; Domenico Coppola; Larry K Kvols
Journal:  J Clin Oncol       Date:  2011-06-27       Impact factor: 44.544

3.  Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients.

Authors:  Jan Franko; Wentao Feng; Linwah Yip; Elizabeth Genovese; A James Moser
Journal:  J Gastrointest Surg       Date:  2009-12-09       Impact factor: 3.452

4.  Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression.

Authors:  Francesco Panzuto; Letizia Boninsegna; Nicola Fazio; Davide Campana; Maria Pia Brizzi; Gabriele Capurso; Aldo Scarpa; Filippo De Braud; Luigi Dogliotti; Paola Tomassetti; Gianfranco Delle Fave; Massimo Falconi
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

Review 5.  Functioning and nonfunctioning neuroendocrine tumors of the pancreas.

Authors:  Elijah Dixon; Janice L Pasieka
Journal:  Curr Opin Oncol       Date:  2007-01       Impact factor: 3.645

Review 6.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

7.  Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours.

Authors:  R Bettini; L Boninsegna; W Mantovani; P Capelli; C Bassi; P Pederzoli; G F Delle Fave; F Panzuto; A Scarpa; M Falconi
Journal:  Ann Oncol       Date:  2008-01-21       Impact factor: 32.976

8.  Pancreatic neuroendocrine tumors: the impact of surgical resection on survival.

Authors:  Joshua S Hill; James T McPhee; Theodore P McDade; Zheng Zhou; Mary E Sullivan; Giles F Whalen; Jennifer F Tseng
Journal:  Cancer       Date:  2009-02-15       Impact factor: 6.860

9.  Are G3 ENETS neuroendocrine neoplasms heterogeneous?

Authors:  Fritz-Line Vélayoudom-Céphise; Pierre Duvillard; Lydia Foucan; Julien Hadoux; Cecile N Chougnet; Sophie Leboulleux; David Malka; Joël Guigay; Diane Goere; Thierry Debaere; Caroline Caramella; Martin Schlumberger; David Planchard; Dominique Elias; Michel Ducreux; Jean-Yves Scoazec; Eric Baudin
Journal:  Endocr Relat Cancer       Date:  2013-08-19       Impact factor: 5.678

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

View more
  6 in total

Review 1.  Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors.

Authors:  Masayuki Tanaka; Max Heckler; André L Mihaljevic; Pascal Probst; Ulla Klaiber; Ulrike Heger; Simon Schimmack; Markus W Büchler; Thilo Hackert
Journal:  Ann Surg Oncol       Date:  2020-07-27       Impact factor: 5.344

Review 2.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

3.  Predicting Progression, Recurrence, and Survival in Pancreatic Neuroendocrine Tumors: A Single Center Analysis of 174 Patients.

Authors:  Sara Krogh; Henning Grønbæk; Anders Riegels Knudsen; Peter Kissmeyer-Nielsen; Nynne Emilie Hummelshøj; Gitte Dam
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-28       Impact factor: 6.055

4.  Survival and prognostic factors analysis of 151 intestinal and pancreatic neuroendocrine tumors: a single center experience.

Authors:  Fanny Foubert; Maëva Salimon; Clotilde Dumars; Nicolas Regenet; Paul Girot; Aurélien Venara; Hélène Senellart; Marie-Françoise Heymann; Tamara Matysiak-Budnik; Yann Touchefeu
Journal:  J Gastrointest Oncol       Date:  2019-02

5.  Impact of tumour size on metastasis and survival in patients with pancreatic neuroendocrine tumours (PNETs): A population based study.

Authors:  Yangyang Liu; Shufang Ye; Yabi Zhu; Xingkang He; Jie Pan; Shujie Chen; Bin Ye; Liangjing Wang
Journal:  J Cancer       Date:  2019-10-18       Impact factor: 4.207

6.  Impact of Surgery on Non-Functional Pancreatic Neuroendocrine Tumors ≤2 cm: Analyses With Propensity Score-Based Inverse Probability of Treatment Weighting.

Authors:  Jingyuan Ye; Hongyu Wu; Jinzheng Li; Changan Liu
Journal:  Front Surg       Date:  2022-07-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.